The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer

Macrophage polarization: reaching across the aisle?

(2019) Maria Carla Bosco   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents

(2018) Matteo Santoni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer

(2018) Valeria Quaranta et al.   CANCER RESEARCH

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

(2018) Elisa Peranzoni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis

(2018) Italia Grenga et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation

(2018) Genevieve P Hartley et al.   Cancer Immunology Research

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

(2018) Karin M. Knudson et al.   OncoImmunology

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

(2018) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Activation of phagocytosis by immune checkpoint blockade

(2018) Chia-Wei Li et al.   Frontiers of Medicine

Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages

(2018) Shicheng Su et al.   CELL

Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models

(2018) Daniel Newsted et al.   OncoImmunology

Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells

(2017) Mengqi Yang et al.   Molecular Oncology

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor macrophages are pivotal constructors of tumor collagenous matrix

(2016) Ran Afik et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis

(2016) Sebastian R. Nielsen et al.   NATURE CELL BIOLOGY

Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan

(2016) W Chen et al.   Cell Death & Disease

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms

(2015) Tamás Rőszer   MEDIATORS OF INFLAMMATION

PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity

(2015) Tong Seng Lim et al.   OncoImmunology

The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells

(2014) Xian-Feng Wang et al.   CELLULAR IMMUNOLOGY

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation

(2014) Jia Xue et al.   IMMUNITY

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Macrophage plasticity and polarization: in vivo veritas

(2012) Antonio Sica et al.   JOURNAL OF CLINICAL INVESTIGATION

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas

(2011) Jie Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice

(2011) Moshe Elkabets et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages duringchronic hepatitis C virus infection

(2010) Cheng J. Ma et al.   IMMUNOLOGY

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

(2010) Junko Matsuzaki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Interferon- -triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells

(2009) B. Jurgens et al.   BLOOD

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

(2009) K. Wu et al.   CANCER RESEARCH

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells

(2009) Hae-Yun Cho et al.   IMMUNOLOGY LETTERS

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

(2009) X. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS